MSD's Sac-TMT delivers in first phase 3 readout
MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.
Novartis reveals more data behind Pluvicto expansion bid
Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.
WHO says Ebola outbreak in Congo is a "public emergency"
As deaths from an Ebola virus outbreak in DRC and Uganda rise above 80, the FDA has declared it a public health emergency of international concern.
AZ gets first okay for new hypertension drug baxdrostat
AstraZeneca is the first company to get FDA approval for an aldosterone synthase inhibitor for hypertension, ahead of rival Mineralys.
Another LAG-3 setback as Regeneron drug fails phase 3 trial
Regeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
6th Rare & Genetic Kidney Disease Drug Development Summit
The 6th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston on August 18–20, 2026, bringing together global leaders advanc
Navigating Change: Key Industry Insights at PHARMAP 2026
PHARMAP returns in 2027 in Berlin, Germany, with Bayer as the Host Sponsor
Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...
EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery
Axtria Acquires Conexus Solutions, Uniting Agentic AI and CR...
Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, today announced the acquisition of Conexus Solutions
PHARMAP 2026: From Vendors to Strategic Partners
Strategic Partnerships at PHARMAP 2026 – Big Pharma’s Shift Toward CDMOs and CMOs